Preclinical studies in small and large animal models using helper-dependent adenoviral vectors (HDAds) have generated promising results for the treatment of genetic diseases. However, clinical translation is complicated by the dosedependent, capsid-mediated acute toxic response following systemic vector injection. With the advancements in vectorology, a better understanding of vector-mediated toxicity, and improved delivery methods, HDAds may emerge as an important vector for gene therapy of genetic diseases and this report highlights recent progress and prospects in this field.
First-generation adenoviral vectors (FGAds), rendered replication-deficient by the deletion of the viral early region 1, can efficiently transduce a wide variety of cell types from many different species independent of the cell cycle to direct high-level transgene expression. However, low-level viral gene expression from the vector backbone in transduced cells renders transgene expression transient. In contrast, helper-dependent adenoviral vectors (HDAds), which are devoid of all viral genes, can provide long-term transgene expression. For this reason, HDAds are preferred over FGAds when long-term expression is required as in the case of gene therapy for genetic diseases. Nevertheless, earlier-generation Ad vectors still have numerous applications when a strong immune reaction is desired such as for cancer gene therapy or for vaccination. This review will focus on the developments and improvements in HDAds for gene therapy of genetic diseases since January 2004.
HDAds provide stable, long-term transgene expression in small and large animal models without chronic toxicity for liver-directed gene therapy
The liver is a very attractive target for gene therapy because it is the affected organ in many genetic diseases, the fenestrated structure of its endothelium permits
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HDAds provide stable, long-term transgene expression in small and large animal models without chronic toxicity for liver-directed gene therapy. High vector doses are required for efficient hepatocyte transduction by systemic administration. Strategies to improve the therapeutic index of HDAd are available or currently under investigation for liver-directed gene therapy. High-efficiency pulmonary transduction and clinically relevant end points can be achieved delivering HDAd in conjunction with tight junction opening agents for CF gene therapy. HDAd delivered with an intracorporeal nebulizing catheter results in high-efficiency transduction of the respiratory epithelium in large animals. Encouraging results have been obtained with HDAd for brain-and muscle-directed gene therapy in animal models.
Prospects
A better understanding of the acute innate response will provide new targets for pharmacological blockade to improve the therapeutic index of the vector. Further optimization of preferential liver targeting by HDAd through balloon catheter delivery has the potential of providing a clinically attractive method of vector delivery. Further assessment of Ad PEGylation and modulation of the liver fenestrations may provide attractive strategies to increase the therapeutic index of the vector. Capsid modification to increase the affinity of Ad for hepatocytes has the potential to improve safety and efficacy. A large animal model for cystic fibrosis is needed to fully evaluate safety and efficacy of airway delivery of HDAd.
exposure of hepatocytes to intravenously delivered vector and it permits secretion of vector-encoded therapeutic proteins into the circulation for systemic delivery. The HDAd has emerged as a very attractive vector for liver-directed gene therapy because, unlike early-generation Ad vectors, they are deleted of all viral coding sequences and thus are less immunogenic, less toxic and can provide long-term transgene expression. 1 For example, a single systemic injection of an HDAd expressing uridine diphospho-glucuronosyl transferase 1 A1 resulted in lifelong (at least 2 years) expression of uridine diphospho-glucuronosyl transferase 1 A1 and permanent correction of the hyperbilirubinemia in the Gunn rat, an animal model for Crigler-Najjar syndrome type I.
2 Long-term expression by HDAd has also been demonstrated in clinically relevant large animal models. For example, intravenous injection of HDAd expressing the canine coagulation factor IX in hemophilia B dogs resulted in sustained phenotypic improvement of the bleeding diathesis for the duration of the experiment of over 1 year after vector administration. 3 These, as well as other recent studies, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] provide compelling evidence for using HDAd to treat genetic disorders.
High vector doses are required for efficient hepatocyte transduction by systemic administration
Unfortunately, relatively high vector doses were required in the aforementioned and other studies to achieve efficient hepatic transduction following systemic intravascular delivery because of a nonlinear dose-response to hepatic transduction; low doses yield very low-toundetectable levels of transgene expression, while higher doses result in disproportionately high levels of transgene expression. Kupffer cells (KCs) of the liver play a significant role in this nonlinear dose response by sequestering intravenous Ad. Furthermore, systemic administration of Ad vectors likely results in widespread transduction of a large number of extrahepatic cell types (for example, blood cells, endothelium, spleen, lung and so on.), which also contributes to inefficient hepatocytes transduction.
Understanding the mechanisms of hepatocyte transduction by Ad is important for optimal gene transfer. Hepatocyte transduction does not appear to be mediated by the coxsackie and adenovirus receptor, but involves either a direct or a blood factor-(coagulation factors IX and complement factors such as the complement component 4-binding protein) mediated binding. 14 In a recently proposed model, factor IX and complement component 4-binding protein bind directly to the Ad fiber and mediate the binding of Ad to alternate receptors, such as heparan sulfate proteoglycans and/ or low-density lipoprotein receptor-related protein. 15 Strategies aimed at altering the tropism of the vector to specifically target hepatocytes could take advantage of this newly recognized model of hepatocyte-Ad interaction.
Systemic injection of early-generation Ad vectors is associated with two phases of toxicity. The first phase is mediated by the capsid and the second by expression of viral genes. While the second phase of toxicity is abolished with HDAd because they lack viral genes, the first phase remains since the viral capsids of all Ad-based vectors are identical. This capsid-mediated toxic response occurs shortly after vector administration and is characterized by high levels of serum inflammatory cytokines and chemokines consistent with activation of an innate inflammatory immune response. 16, 17 Importantly, the severity of the acute toxic response is dosedependent. In humans, a dose of 6 Â 10 11 vp kg À1 of a second-generation Ad vector (early region 1, E4-deleted) was lethal in one of two partial ornithine transcarbamylase-deficient patients following hepatic artery injection.
Understanding the mechanism responsible for the innate inflammatory response to Ad vectors is essential for developing strategies to improve the safety and efficacy of Ad-mediated gene therapy. However, this response is extremely complex and includes a multitude of cellular and humoral factors that are only partially understood. Systemic administration of Ad vectors results in widespread interactions with a large number of extrahepatic cell types (for example, blood cells, endothelium, spleen, lung and so on) all of which may contribute to activation of the innate immune response. 1 For example, within the blood Ad vector interacts with human plasma components (notably adenovirus typespecific antibodies) and blood cells. Over 90% of the vector dose appears to be stably associated with human erythrocytes ex vivo.
18 Ad particles also rapidly bind directly to circulating platelets and the Ad platelet aggregates are taken up by KCs within the liver sinusoids. 19 Thrombocytopenia has been consistently reported following the administration of Ad vectors and the exact mechanism underlying this phenomenon is currently unknown. It has been demonstrated, however, that Ad can activate platelets, induce platelet-leukocyte aggregate formation and endothelial cell activation via the action of the von Willebrand factor. 20 Whether in the form of aggregates with platelets or as free viral particles, the reticuloendothelial system in the liver and spleen sequesters the majority of the vector, 21 and may contribute to the activation of the innate immune response triggered by Ad. Interestingly, it has been shown by hydrodynamic injection of HDAd that high-efficiency hepatic transduction, including high uptake of virions by KCs, did not provoke a strong elevation in interleukin (IL)-6 and IL-12. 22 Instead, this study suggested that systemic, extrahepatic exposure to the vector may play a significant role in the severity of the acute toxic response. Similarly, systemic injection of Ad at doses of 410 11 vp kg À1 , causes rapid KC death in the mouse liver but does not result in elevation of IL-6. 21 However, the interaction between Ad and KCs does appear to trigger a series of cardiovascular responses, including heart rhythm disturbance, a decrease in blood pressure and ischemic events after systemic high-dose injection. 23 Toll-like receptors (TLRs) are crucial components in pathogen recognition processes and are emerging as important players in Ad-mediated acute toxicity. [24] [25] [26] [27] [28] [29] [30] Upon TLR activation, an increased production of cytokines triggers dendritic cell maturation and development of functional T-and B-cell responses aimed at inhibiting pathogen replication. This proinflammatory cytokine burst occurs as a result of the activation of the myeloid differentiation primary response gene 88 and HDAd-mediated gene therapy N Brunetti-Pierri and P Ng leads to nuclear translocation of nuclear factor kB. To date, 11 TLRs have been identified in mammals but the individual role of TLRs in innate immunity is only partially characterized. TLR9 is localized in late endosomes or lysosomes, where it detects unmethylated CpG motifs in dsDNA, and appears to be directly involved in Ad-mediated acute toxicity. 28 The expression of several other TLRs has been shown in vitro to be altered following Ad exposure 26 and it is likely that TLRs are also involved in viral capsid recognition. A further understanding of the mechanism of Ad-mediated activation of the innate immune response may help to identify components that can be pharmacologically modulated to inhibit the acute inflammatory response elicited by Ad vectors. However, the apparently redundant pattern of Ad recognition makes this task extremely difficult. Blocking only one component of this network, for example TLR9, has only a minimal impact on the acute toxic response triggered by Ad vectors in vivo.
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In summary, the precise mechanism responsible for activation of the acute inflammatory response by systemic Ad is multifactorial and complex and remains to be fully elucidated. However, regardless of the precise mechanism, it is clear that this acute toxicity is dosedependent and that a threshold of innate immune activation must first be attained before severe and lethal acute toxicity manifests. Therefore, strategies to achieve high-efficiency hepatic transduction using low vector doses, such as genetic modification of the Ad vector to increase its hepatotropism and physical or pharmacological strategies to target the vector preferentially into the liver, may have significant clinical potential.
In preclinical studies for liver-directed gene therapy adeno-associated viral (AAV) vectors, such as HDAds, have shown to provide long-term transgene expression in mouse, dog and nonhuman primate models. However, despite these encouraging preclinical studies, the outcome of AAV-mediated, muscle and liver-directed hemophilia B gene therapy clinical trials have been disappointing with subtherapeutic levels of expression, transient durations of expression and transaminitis in the liver-directed approach. 31 This outcome was unexpected based on studies in animals and appears to be due to an AAV capsid-specific CD8(+) T-cell immune response against the transduced cells. 32 Based on this experience with AAV, it will be important to determine whether a similar immune reaction will occur in humans following transduction by HDAd.
Strategies to improve the therapeutic index of HDAd are available or currently under investigation for liver-directed gene therapy
Various approaches have been investigated to overcome the threshold to hepatic transduction and to reduce the systemic vector dissemination. Hodges et al. 33 used a balloon occlusion catheter placed in one of the hepatic veins of rabbits to deliver Ad specifically into one liver lobe and found higher hepatic transduction efficiency compared to systemic peripheral intravenous injection. Interestingly, this method of local delivery resulted in hepatic transduction in the presence of neutralizing antiAd antibodies. In another approach, intraportal injection of HDAd administered directly into the surgically isolated liver in nonhuman primates resulted in higher-efficiency hepatic transduction with reduced systemic vector dissemination and stable, high-level, long-term transgene expression for the duration of the observation period of at least 665 days in one animal and at least 476 days in two other animals ( Figure 1 ). 34 Importantly, no chronic toxicity was evident during the entire observation period of this study. However, although encouraging, this method of vector delivery is quite invasive. Another strategy is the direct injection of Ad vectors into the hepatic parenchyma, 35 which resulted in higher transgene expression, reduced vector dissemination and lower inflammatory response when compared to systemic tail vein injection in mice. Moreover, when a relatively low dose of vector was used, intravenous administration resulted in no detectable protein expression whereas the intrahepatic administration resulted in high levels of transgene expression and no inflammation. 35 It is now clear that the liver microarchitecture plays a critical role in determining the efficiency of hepatocyte transduction by Ad vectors. The liver fenestrations normally form a structural barrier preventing large circulating macromolecules in the hepatic blood from accessing the hepatocytes. Several studies suggest that the size of the endothelial fenestrations of the liver (p100 nm) plays a key role in the efficiency of Ad-mediated hepatocyte transduction (Ad virion X100 nm). 36, 37 Specifically, there is a positive correlation between the size of the fenestrations and the efficiency of hepatic transduction following systemic administration HDAd-mediated gene therapy N Brunetti-Pierri and P Ng of Ad. 36 One approach to increase hepatic transduction efficiency may be to use drugs which enlarge liver fenestrations. Indeed, Na-decanoate 36 or N-acetylcysteine combined with transient liver ischemia 37 have been shown to increase the size of the sinusoidal fenestrae and increase Ad-mediated hepatocyte transduction. However, further studies are needed to determine the real clinical potential of these pharmacological approaches for human applications. Another approach is to enlarge the fenestrations by increasing the intrahepatic pressure by hydrodynamic injection. 22 For example, hydrodynamic injection of HDAd resulted in increased hepatic transduction, reduced systemic vector dissemination and reduced proinflammatory cytokines compared to conventional injection in mice. 22 It is believed that the rapid injection of the large volume increases intrahepatic pressure, thereby enlarging the p100 nm fenestrations to permit extravasation of the X100 nm HDAd virions thus facilitating vector-hepatocyte contact. Unfortunately, hydrodynamic injection as performed in mice is not applicable in humans due to the rapid injection of large volumes. However, considering its tremendous potential, a minimally invasive method to mimic hydrodynamic injection but without rapid, large volume injection was developed using balloon occlusion catheters to achieve preferential hepatic delivery of the HDAd (Figure 2) . 38 In this method, hepatic venous outflow is occluded using two balloon occlusion catheters percutaneously placed in the inferior vena cava, above and below the hepatic veins in nonhuman primates ( Figure 2) . As blood entering the liver from the hepatic artery and portal vein remains unobstructed, an increase in intrahepatic pressure is achieved, mimicking the high pressures achieved by systemic hydrodynamic injection in the mice. This pseudo-hydrodynamic injection method resulted in high-efficiency hepatic transduction with minimal toxicity and stable, long-term transgene expression for at least 413 days. 38 Further improvements in balloon catheter delivery of HDAd preferentially into the liver to enhance safety and efficacy have recently been reported. 39 Other potential strategies for overcoming the activation of the innate immune response include masking of the virion capsid by polyethylene glycol (PEG). At least three independent groups have demonstrated that systemic administration of PEGylated Ad into mice resulted in a 50-70% reduction in serum IL-6 compared to unPEGylated vector without compromising hepatic transduction efficiency. [40] [41] [42] In one study, the combination of methylprednisolone and PEGylated Ad potently inhibited IL-6 elevation. 42 Similar encouraging results of reduced IL-6 and IL-12 elevations have recently been reported in nonhuman primates injected with PEGylated HDAd. 43 Although the precise mechanism of how PEGylation attenuates the acute inflammatory response is not fully understood, it nevertheless offers an intriguing and potentially important avenue for increasing the therapeutic index of HDAd.
High-efficiency pulmonary transduction and clinically relevant end points can be achieved delivering HDAd in conjunction with tight junction opening agents for CF gene therapy
First-generation adenoviral vectors were once thought to be the ideal vector for cystic fibrosis (CF) gene therapy but enthusiasm has waned because it was subsequently discovered that transduction of the airway epithelium was inefficient and because pulmonary inflammation occurred due to expression of viral genes from the vector backbone. Inefficient transduction is due to the tight junctions of the airway epithelium cells that prevent the vector from accessing the receptors on the basolateral surface of the cells. 
HDAd delivered with an intracorporeal nebulizing catheter results in high-efficiency transduction of the respiratory epithelium in large animals
A clinically relevant method of vector delivery using an intracorporeal nebulizing catheter to aerosolize HDAd directly into the trachea and lungs of rabbits has been developed. 44 This method was used to aerosolize HDAd expressing LacZ formulated in L-a-lysophosphatidylcholine (LPC; to open tight junctions) into the lungs of rabbits and resulted in extensive transduction of the airway epithelium in the trachea and lung (Figure 3) . 44 For example, 66% of the airway epithelial cells in the trachea were transduced. All rabbits, including those Figure 2 Pseudo-hydrodynamic injection of HDAd into nonhuman primates. 36 Two balloon occlusion catheters are percutaneously positioned in the inferior vena cava (IVC) above and below the hepatic veins (HV). Inflation of the balloons results in hepatic venous outflow occlusion from the HV, while blood inflow from the portal vein (PV) and hepatic artery (HA) increases the intrahepatic pressure. Following 30 min of occlusion, the balloon occlusion catheters are removed from the animal and HDAd is administered by systemic peripheral intravenous injection.
HDAd-mediated gene therapy
N Brunetti-Pierri and P Ng given only LPC as controls, exhibited a transient decrease in dynamic lung compliance immediately following aerosol delivery as well as fever and mild-tomoderate patchy pneumonia without edema, leading the investigators to speculate that the LPC may have been a contributing factor and that these adverse effects may be eliminated/minimized by further optimizing the dose of LPC. Nevertheless, this study is significant because it demonstrated the ability of HDAd to achieve highefficiency transduction of all cell types, including submucosal glands, in the proximal and distal airway epithelium from the trachea to terminal bronchioles in a large animal model (Figure 3 ) that had previously been a major obstacle for CF gene therapy. This strategy of delivering HDAd to rabbits has recently been applied to nonhuman primates and has yielded similar encouraging results.
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HDAd for brain gene therapy
Because of their ability to infect postmitotic cells, including cells of the central nervous system, and to mediate long-term transgene expression, Ad-based vectors are particularly attractive for brain gene therapy. FGAd-mediated transduction of adult brain cells results in minimal, transient local inflammation, which does not compromise sustained transgene expression. However, loss of transgene expression and chronic inflammation are observed following transduction with FGAd if a peripheral immune response against Ad is elicited after natural infection. However, the loss of transgene expression under the same circumstances does not occur following transduction with HDAd. 47 Moreover, HDAd can provide sustained long-term transgene expression in the brain, even in animals pre-immunized against Ad. 48 Recently, interesting results for central nervous system gene therapy have been generated by delivering HDAd into the cerebrospinal fluid by lumbar puncture in nonhuman primates. 49 These studies showed that HDAd given by this route of administration result in long-term (at least 3 months) transgene expression without systemic or local toxicity in animals with pre-existing antiadenoviral immunity.
In specific disease applications, a significant inhibition of huntingtin protein aggregation has been recently reported in a Huntington's disease animal model following stereotaxic injection into the striatum of an HDAd expressing a short hairpin RNA silencing the Huntington disease gene. 13 While encouraging, further studies are needed to assess the efficacy of this treatment using clinically relevant end points.
HDAd for muscle gene therapy
Because of lack of effective treatments, Duchenne muscular dystrophy (DMD) has been considered a prime candidate for gene therapy, the goal of which is to transfer normal copies of the dystrophin gene into the muscle fibers of affected patients. The length of the dystrophin cDNA (14 kb) precluded its inclusion into most gene therapy viral vectors. However, HDAds with their large cloning capacity (up to 37 kb) can accommodate not only one full-length dystrophin cDNA but also two copies of the gene. 9 HDAds expressing fulllength dystrophin have been shown to restore the full dystrophin-glycoprotein complex in the skeletal muscle, resulting in a reduced level of muscle degeneration and amelioration of the physiological and pathological indices of muscle disease. 9 However, in mouse models, intramuscular injection of HDAd expressing speciesspecific dystrophin results in inflammatory infiltrates and a humoral immune response against the dystrophin protein. A similar outcome may occur in humans as well, as many DMD patients have large dystrophin gene deletions. To overcome this problem, several strategies have been successfully utilized including co-delivery of immunomodulatory molecules such as CTL4Aig, 10, 50 and use of an alternative transgene such as utrophin, a functional homolog of dystrophin. 51 HDAds have also been explored for in utero gene therapy of DMD. The immaturity of the immune system of the fetus coupled with the survival advantage of dystrophin-expressing HDAd-mediated gene therapy N Brunetti-Pierri and P Ng muscle fibers over dystrophin-deficient muscle fibers may offer a significant advantage for this promising therapeutic strategy. In this approach, HDAds were found to be less toxic than the FGAd and able to drive stable transgene expression and restoration of the disarcoglycan complex. 52 Respiratory insufficiency due to progressive weakness of the diaphragm and other respiratory muscles is the main cause of death of DMD patients when they are in their late teens or early twenties. Therefore, diaphragmdirected gene therapy has been investigated in the mdx mouse using HDAd injected directly into the diaphragm exposed through a laparotomy. 11 This approach has led to reversal of functional abnormalities of dystrophic diaphragms but at the same time it also points to the difficulties of DMD gene therapy, which, in order to be effective, requires the transduction of a critical number of muscle fibers throughout the body.
Prospects
Preclinical studies in small animal models using HDAd have demonstrated tremendous potential for liver, lung, brain and muscle-directed gene therapies for genetic diseases. Despite encouraging and compelling results, translation to large animal models has been more challenging and concerns remain for clinical applications. For liver-directed gene therapy, acute toxicity provoked by the viral capsid is the most significant obstacle currently hindering clinical applications. Studies to elucidate the mechanism(s) of Ad-mediated activation of the innate inflammatory response are in progress and a better understanding of this phenomenon will likely allow for the development of strategies to minimize, if not eliminate, the problem of acute toxicity. Strategies to improve hepatocyte transduction by these vectors are also currently under investigation and their optimization may allow for therapeutic levels of transduction using low, nontoxic doses.
Several outstanding issues remain to be addressed in the case of CF gene therapy. The efficiency of transduction will likely be greatly reduced in severely diseased CF lungs, possibly rendering it necessary to treat less affected lungs that may be more amenable to gene transfer. Moreover, antiadenovirus immune responses, such as cytotoxic T-lymphocyte responses and major histocompatibility complex class I antigen presentation, may be further enhanced if the host has a pre-existing Pseudomonas aeruginosa infection. 53 In addition, the requirement to transiently disrupt tight junctions to achieve efficient transduction raises safety concerns as this may allow bacteria to penetrate the epithelium, especially for CF patient airway epithelium colonized with several microbial pathogens. However, this potential concern should be weighed against potential benefits, and intravenous and inhaled antibiotics routinely prescribed to CF patients could be administered prophylactically around the time of gene therapy. Additionally, the duration of pulmonary transgene expression from HDAd remains unknown. In the case of liver-directed gene therapy, HDAd has been shown to mediate stable transgene expression for more than 1 year. However, the rate of turnover of airway epithelial cells is greater than hepatocytes and may likely be even greater in the CF lung. Moreover, vector readministration may be challenging due to an adaptive humoral immune response against the viral capsid. To overcome this, strategies such as transient immunosuppression at the time of vector administration, masking the vector with PEG, or switching to a different serotype vector, have been tried with some success for intrapulmonary readministration with FGAd but not with HDAd.
However, Koehler et al. 54 have recently demonstrated that simple readministration of HDAd of the same serotype, but not FGAd, can lead to successful pulmonary transduction. In this study, a second administration of HDAd to the mouse lung was possible with minimal loss of transgene expression. These results were in sharp contrast to those obtained with FGAd in which transgene expression was significantly reduced following the second vector administration. In addition, lower concentrations of antibodies against Ad were found in lung lavage fluid and serum from mice that received HDAd as compared to those that received FGAd, suggesting that readministration of HDAd to the airway may be more efficient than FGAd. There is also a clear need for a large animal model for CF that faithfully recapitulates the human disease to fully evaluate the safety and efficacy of HDAd-mediated as well as other gene therapy strategies. Further improvements in current technologies and development of novel strategies must be pursued to make CF gene therapy a clinical reality, and based on the encouraging and compelling studies showing very limited toxicity of the vector administered through the airway even at doses achieving extensive transduction of the respiratory epithelium, 46 HDAd may yet emerge to play an important role in CF gene therapy.
